Jolt Health Inc.

JOLT

CA4798611063

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 11:17:07 2024-07-09 am EDT			5-day change	1st Jan Change
0.005 ^CAD	0.00%		0.00%	0.00%

May. 24	Jolt Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Jolt Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Love Pharma Inc. Names Zach Stadnyk as CEO

September 30, 2021 at 07:51 am EDT

Love Pharma Inc. announced that As part of the acquisition transaction, Zach Stadnyk of Vancouver, BC, has joined the board and has assumed the role of CEO, with Doug Taylor remaining on the board.

Latest news about Jolt Health Inc.

Jolt Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 24	CI
Jolt Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Jolt Health Inc. announced that it has received CAD 0.5 million in funding	Mar. 26	CI
Jolt Health Inc. Announces Board Changes	Mar. 08	CI
Jolt Health Inc. announced that it expects to receive CAD 0.5 million in funding	Mar. 07	CI
Jolt Health Inc. announced that it expects to receive CAD 0.38 million in funding	Nov. 21	CI
Jolt Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Jolt Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Jolt Health Inc. announced that it has received CAD 0.099875 million in funding	23-07-18	CI
Jolt Health to Seek Acquisitions	23-06-16	CI
Jolt Health Inc. announced that it expects to receive CAD 0.4 million in funding	23-06-14	CI
Jolt Health Inc. Announces Gerald Tritt Joined the Company as A Director	23-06-02	CI
Jolt Health Inc. Announces Gerald Tritt Joins the Company as CEO	23-06-02	CI
Jolt Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Love Pharma Inc. will Change its Ticker to JOLT from LUV	23-05-22	CI
Love Pharma Inc. will Change its Name to Jolt Health Inc	23-05-22	CI
Love Pharma Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
Jolt Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
LOVE Pharma Inc. to Evaluate Mining Opportunities	23-04-05	CI
An unknown buyer acquired MicroDoz Therapy Inc from Love Pharma Inc. for CAD 0.1 million.	22-12-13	CI
Love Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Love Pharma Inc. Announces Board Changes	22-11-02	CI
Love Pharma Inc. completed the acquisition of Doc Hygiene Pharmaceuticals Inc.	22-10-18	CI
LOVE Pharma Provides an Update on the Launch of its Psilocybin Trials at John Hopkins University	22-10-18	CI
Love Pharma Co. Provides Update on the Advancement of the Previously Announced Trial Focused Upon Clinical Applications for Psilocybin Assisted Therapy for Addiction to Be Conducted at Johns Hopkins	22-10-13	CI

Jolt Health Inc. is a Canada-based life sciences company focused on healthcare, biotechnology and artificial intelligence. The Company holds licenses for therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America. The Company's Wellness Product Portfolio is comprised of wellness products and the underlying intellectual property, concentrating on sexual health, with or without the benefit of CBD, acquired pursuant to various product licenses. In particular, the Company has rights to utilize a range of products and the related intellectual property pursuant to the product licenses, including CBD oral strips, Arouse RX gel with CBD and/or THC, CBD/THC biphasic mints/candies, Female Sexual Dysfunction supplement (FSD Supplement), ToConceive, and Male Enhancement Gel With CBD.

Sector

Pharmaceuticals

Calendar

2025-04-29 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOLT HEALTH INC.	0.00%	467K
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B